Purpose: The purpose of this study was to describe a case of bilateral peripapillary choroidal neovascular membranes in the setting of a patient with papillitis associated with pembrolizumab for Stage IIIA adenocarcinoma of the lung.
Methods: This was a retrospective case report with fundus photography, fluorescein angiography, optical coherence tomography, and optical coherence tomography angiography.
Results: A 59-year-old woman with Stage IIIA adenocarcinoma of the lung on pembrolizumab therapy presented with symptoms of blurry vision. She was found to have bilateral papillitis with right eye peripapillary subretinal hemorrhage and serous retinal detachment involving the fovea. Fluorescein angiography suggested peripapillary neovascularization with leakage in both eyes. Intravitreal bevacizumab injections were given in both eyes on a monthly basis with dramatic resolution of subretinal hemorrhage and fluid and control of peripapillary choroidal neovascular membranes.
Conclusion: Pembrolizumab has been associated with many ocular adverse effects, and to the best of our knowledge, we report the first case of pembrolizumab associated with papillitis and peripapillary choroidal neovascular membranes. Control of the neovascularization was achieved with antivascular endothelial growth factor therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ICB.0000000000001254 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bilateral Choroidal Metastases from Primary Cutaneous Melanoma Following Nivolumab Discontinuation: A Case Report.
Ocul Immunol Inflamm
January 2025
Ocular Oncology Service, Institute of Oncology, Tecnologico de Monterrey, Monterrey, Mexico.
Purpose: To present the case of a young patient with BRAF V600E-mutant cutaneous melanoma who developed bilateral choroidal metastases complicated by neovascular glaucoma (NVG) in both eyes following the interruption of nivolumab therapy.
Methods: A 28-year-old female with primary cutaneous melanoma of the left hand underwent surgical resection and adjuvant nivolumab. Immunotherapy was discontinued due to immune-related acute interstitial nephritis.
DNA Methyltransferase Expression (DNMT1, DNMT3a, and DNMT3b) as a Potential Biomarker in Age-Related Macular Degeneration.
J Clin Med
January 2025
H&TRC-Health & Technology Research Center, ESTeSL-Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, 1990096 Lisbon, Portugal.
Age-related macular degeneration (AMD) is a global cause of vision loss, with limited therapeutic options highlighting the need for effective biomarkers. This study aimed to characterize plasma DNA methyltransferase expression (, , and ) in AMD patients and explore divergent expression patterns across different stages of AMD. : Thirty-eight AMD patients were prospectively enrolled and stratified by disease severity: eAMD, iAMD, nAMD, and aAMD.
View Article and Find Full Text PDFPostpartum Exudation of Idiopathic Quiescent Macular Neovascularization: A Narrative Review with a Related Case Report.
Life (Basel)
December 2024
Eye Unit, Department of Medicine, Surgery, and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, SA, Italy.
The abnormal growth of irregular new blood vessels into the subretinal or intraretinal space is known as macular neovascularization (MNV). People over 50 are often affected by this disorder, which is typically brought on by age-related macular degeneration. In addition, MNV can be found in people under 50 years of age, who may present primary ophthalmic diseases such as pathological myopia, angioid streaks, traumatic choroidal rupture, or suspected ocular histoplasmosis syndrome.
View Article and Find Full Text PDFThe clinical effects and mechanism of action of ranibizumab in treating myopic choroidal neovascularization.
Int Ophthalmol
January 2025
Department of Ophthalmology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215008, Jiangsu, China.
Purpose: Myopic choroidal neovascularization (CNV) is a common reason for visual impairment. This study investigated the clinical effects of repeated intravitreal injections of ranibizumab among patients with CNV secondary to pathologic myopia.
Methods: This study involved a single-center, non-randomized clinical prospective cohort research design including 39 patients with myopic CNV and a control group of 10 patients with cataract.
[Differential diagnoses of central serous chorioretinopathy : Is that really a central serous chorioretinopathy?].
Ophthalmologie
January 2025
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland.
The accurate diagnosis of central serous chorioretinopathy (CSC) and its distinction from differential diagnoses is crucial for effective patient counseling and treatment. This is achieved through a targeted patient history and multimodal imaging, which distinguish CSC from other ocular diseases also characterized by subretinal fluid and changes in the retinal pigment epithelium. In this article we identify the key differential diagnoses of CSC and illustrate the characteristic differential diagnostic features of each disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!